Celyad Oncology

CYAD:NASDAQ
RT Quote | NASDAQ | USD
Last | 01/15/21 EST
8.43quote price arrow down-0.01 (-0.12%)
Volume
10,151
52 week range
4.10 - 13.01

...

Loading . . .

KEY STATS

  • Open8.59
  • Day High8.59
  • Day Low8.30
  • Prev Close8.44
  • 52 Week High13.01
  • 52 Week High Date06/04/20
  • 52 Week Low4.10
  • 52 Week Low Date03/18/20
  • Market Cap116.63M
  • Shares Out13.94M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta1.54
  • 1 Year % Change-26.04

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date03/26/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Celyad Oncology News

There is no recent news for this security.

Latest CYAD News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists...
Michel Lussier
Chairman
Filippo Petti
Chief Executive Officer
Gaetane Metz
Chief Operating Officer
Richard Mountfield
Vice President
Carri Duncan P.h.D.
Vice President
Address
Axis Business Park Rue Edouard Belin 2
Mont-saint-guibert
1435
Belgium